tumor-immune-microenvironment

Documents about tumor-immune-microenvironment

• Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment#876712ClinicalTrials.gov
• Mechanisms of tumor cell evasion from NK cell-mediated killing and advances in NK cell-based cancer immunotherapy#4574Europe PMC
• Bibliometric and visual analysis of global research trends and frontiers in the tumor microenvironment and immune escape.#368323NCBI PubMed Central
• Glioblastoma as a neuro-immune network disorder: rethinking the tumor microenvironment, neural circuit integration, and therapeutic resistance.#446235NCBI PubMed Central
• Steroidogenesis is associated with bladder cancer progression via reprogramming the metabolic landscape of the tumor immune microenvironment.#785612NCBI PubMed Central
• The role of pathology in immunotherapy and targeted therapy for renal cell carcinoma#268874IRIS
• PSMA-specific CAR-T Cell Therapy#873141ClinicalTrials.gov
• Decoding the CAF-TAM axis: multi-omics dissection and therapeutic targeting of stromal-immune crosstalk in the tumor microenvironment.#242353NCBI PubMed Central
• Figure 1 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246353Figshare
• Figure 2 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246354Figshare
• Figure 3 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246355Figshare
• Figure 4 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246356Figshare
• Figure 5 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246357Figshare
• Figure 6 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246358Figshare
• Single-cell landscape of peripheral and tumor-infiltrating immune cells in HPV-negative HNSCC.#9580PubMed
• Supplementary Figure S1 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246359Figshare
• Supplementary Figure S2 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246360Figshare
• Supplementary Figure S3 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246361Figshare
• Supplementary Figure S4 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246362Figshare
• Supplementary Figure S5 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246363Figshare
• Supplementary Figure S6 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246364Figshare
• Supplementary Figure S7 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246365Figshare
• Supplementary Figure S8 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246366Figshare
• Supplementary Table 1 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246367Figshare
• Supplementary Table 2 from CD4⁺ T Cells Sensitize Quasimesenchymal Breast Tumors Lacking CD73 to Anti-CTLA4 Immune Checkpoint Blockade Therapy#246368Figshare
• Impact of stromal maturity and proportion on prognosis and immune landscape in colorectal cancer.#9602PubMed
• Glycosylation as a Universal Regulator of Pathogenesis and Therapeutic Target in Multifactorial Human Diseases#990509Zenodo (CERN)
• Using Cyclic Immunofluorescence (CyCIF), Deep-learning, and Human Tumor Microarrays (hTMAs) for Antibody Validation and Creation of an Atlas of Cancers Emphasizing Unique Phenotypes#643572Harvard DASH
• Repurposing licensed viral vaccines as anti-cancer therapeutics: Turning cold tumors hot#478495Europe PMC
• TIME in Immunotherapy Combined With nCRT for Rectal Cancer#1032629ClinicalTrials.gov
• Integrated bioinformatics and experimental validation identifies CLIC6 as a novel tumor suppressor regulating NF-κB signaling and immune microenvironment in nasopharyngeal carcinoma.#174538NCBI PubMed Central
• Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma#408745HAL (France)
• Table 1_Global research trends and emerging frontiers of intratumoral microbiota in cancer immunotherapy: a bibliometric and visualization analysis.docx#384349Figshare
• Distant antimestastatic effect of enterotropic colon cancer-derived a4b7+ CD8+ T cells#326171HAL (France)
• Effects of High-Fiber Diet on Gut Microbiota, Metabolism, and Immune Microenvironment in Solid Tumor Patients: A Clinical Study#398322ClinicalTrials.gov
• Leveraging the bacteria for enhanced cancer immunotherapy: from a perspective of synthetic biology#266487Europe PMC
• The mechano-immunological landscape in the tumor microenvironment: From mechanical sensing to a new therapeutic paradigm#307852Europe PMC
• Single-Cell and Machine Learning Analyses Identify MYDGF as an Immune-Related Biomarker Associated With the Tumor Microenvironment in Clear Cell Renal Cell Carcinoma.#404343NCBI PubMed Central
• Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors#178205HAL (France)
• Splicing factor HNRNPD and alternative splicing of MAP4K4 are associated with cell apoptosis and immune microenvironment features in Wilms’ tumor#434554PLOS
• Rôle de l'infiltrat immun dans la réponse au traitement dans les cancers des voies aéro-digestives supérieures#468345HAL (France)
• Naltrexone and Propranolol Combined With Immunotherapy#892860ClinicalTrials.gov
• E2F1-induced IL6 mediates cancer-immune cell crosstalk by modulating T cell response in tumor microenvironment that regulates metastatic properties in melanoma#389831RosDok
• Spatial transcriptomics unveils immune cellular ecosystems associated with patient survival in diffuse large B-cell lymphoma.#123386PubMed
• Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLC#1015719Europe PMC
• Image 1_Single-cell transcriptomic profile unveils distinct immune ecosystems in alcohol- and nonalcohol-associated hepatocellular carcinoma.tif#460283Figshare
• Table 3_Single-cell transcriptomic profile unveils distinct immune ecosystems in alcohol- and nonalcohol-associated hepatocellular carcinoma.xlsx#460284Figshare
• Table 2_Single-cell transcriptomic profile unveils distinct immune ecosystems in alcohol- and nonalcohol-associated hepatocellular carcinoma.xlsx#460285Figshare
• Image 9_Single-cell transcriptomic profile unveils distinct immune ecosystems in alcohol- and nonalcohol-associated hepatocellular carcinoma.tif#460286Figshare
• Table 1_Single-cell transcriptomic profile unveils distinct immune ecosystems in alcohol- and nonalcohol-associated hepatocellular carcinoma.docx#460287Figshare